Bristol-Myers Squibb says it withdrew US antitrust paperwork for Celgene buy, will refile Feb. 20
MLex Summary: Bristol-Myers Squibb said that it has withdrawn antitrust paperwork for its proposed acquisition of Celgene in order to facilite continued dialogue with the US Federal Trade Commission. The company...To view the full article, register now.
Already a subscriber? Click here to view full article